###### Article summary

Strengths and limitations of this study
=======================================

-   A large population-based study using routinely collected healthcare data with generalisable results.

-   Chronic kidney disease (CKD) categories were based on one estimated-glomerular filtration rate measurement.

-   Not all patients reclassified out of CKD had data available for cardiovascular risk assessment and the extent of missed high-risk patients with CKD-EPI may be underestimated.

Introduction {#s1}
============

Chronic kidney disease (CKD) is common and causes substantial morbidity, mortality and healthcare expenditure because it is associated with an increased risk of cardiovascular events as well as progression to end-stage renal failure.[@R1; @R2; @R3] Estimated glomerular filtration rate (eGFRs) are routinely calculated from measured serum creatine values to assess renal function.[@R4] The eGFR is central to the classification of CKD into different stages and is used alongside other evidence of kidney disease, such as structural abnormalities on imaging or albuminuria. A key consequence of this staging of CKD is that it is used to guide the management of cardiovascular risk markers, the frequency of follow-up and the need for referral.[@R4] In The Netherlands there is guidance for primary care on how to assess and manage cardiovascular risk.[@R5]

Globally, the standard equation used by healthcare laboratories to calculate eGFR is the four variable Modification of Diet and Renal Disease (MDRD) study equation.[@R6] Using pooled data from diagnostic accuracy studies, a newer more accurate equation was developed---the chronic kidney disease epidemiological collaboration (CKD-EPI) equation.[@R7; @R8; @R9; @R10] Several studies have shown that use of the CKD-EPI equation to calculate eGFR leads to a reduction in CKD diagnoses in younger patients, but an increase in CKD diagnoses in elderly patients.[@R11] [@R12] Data from cohort studies and the US health insurance schemes have shown that CKD stage derived from the CKD-EPI formula better predicts cardiovascular events and cardiovascular risk than does CKD stage derived from the MDRD equation.[@R13; @R14; @R15]

The impact on cardiovascular risk follow-up and management in primary care arising from the introduction of the CKD-EPI formula for routine eGFR reporting has not been assessed. We do know that the CKD-EPI formula will change the CKD stage of many patients.[@R11] This has important implications as current guideline-driven care pathways emphasise different intensities of monitoring and drug prescribing according to CKD stage. For patients who have their CKD diagnosis removed entirely (by a shift from an MDRD-derived eGFR of \<60 to a CKD-EPI-derived eGFR of \>60 mL/min/1.73 m^2^ in the absence of known albuminuria or other evidence of kidney disease) this will lead to a less intensive treatment of cardiovascular risk factors unless there are comorbid diagnoses such as diabetes mellitus that necessitate enrolment in a cardiovascular risk management programme.

In The Netherlands, all routine chronic disease management is undertaken by primary care physicians in community-based practices, and national guidance on monitoring is available.[@R4] Reporting of eGFR with serum creatine in The Netherlands began in 2006 and the EuroSCORE model for cardiovascular risk assessment is currently recommended for use in primary care.[@R5] The aim of the study was to determine the cardiovascular risk profile of patients who no longer fulfilled CKD stage 3 criteria when using the CKD-EPI formula for eGFR reporting.

Method {#s2}
======

Recruitment of patients {#s2a}
-----------------------

This study used patient data from general practices that participated in a cluster randomised controlled trial on the effect of web-consultation between a general practitioner (GP) and nephrologist on face-to-face referrals---the CONTACT study (Consultation of Nephrology by Telenephrology Allows optimal Chronic kidney disease Treatment in primary care, Netherlands Trial Registration code 2368). The CONTACT study recruited practices during a CKD management course for GPs in the eastern Netherlands. Forty-seven non-academic general practices participated and in the current study the latest data were analysed from their registered populations' electronic medical records between 1 January 2008 and 30 June 2011.

Estimation of renal function {#s2b}
----------------------------

eGFRs were calculated for patients aged 18 years or older using both the MDRD and CKD-EPI equations.[@R6] [@R7] The most recent serum creatine values were selected and were either standardised to isotope dilution mass spectrometry (IDMS) or subject to the appropriate correction factor for laboratories using the Jaffé technique.[@R16]

Patient characteristics {#s2c}
-----------------------

Demographic and clinical data including age, sex, albuminuria, comorbidities, medication, blood pressure and lipid levels were extracted from electronic medical records ([table 3](#BMJOPEN2013003631TB3){ref-type="table"}). Albuminuria was divided into microalbuminuria and macroalbuminuria. Microalbuminuria was defined as a urinary albumin to creatine ratio (ACR) of 2.5--25 mg/mmol in men and 3.5--35 mg/mmol in women. Higher ratios were considered to reflect macroalbuminuria. If the ACR was not available we used a urine albumin concentration \>20--200 mg/L for microalbuminuria and \>200 mg/L for macroalbuminuria.[@R17] Comorbidities were classified using the International Classification of Primary Care (ICPC) codes as a history of the following diseases: cardiovascular disease (CVD) (K74-K77, K89, K90, K92), diabetes mellitus (T90) and hypertension (K86, K87). Anatomical therapeutic chemical (ATC) codes were used to select prescriptions from 2010, and included ACE inhibitors and angiotensin receptor blockers (C09), diuretics (C03) and statins (C10). Blood pressure was reported as the mean of the two most recent measurements. In order to reduce potential under ascertainment bias for chronic disease, if patients were prescribed medications for chronic disease management without an appropriate code, for example, antihypertensive medication without hypertension coded in the medical record, we assumed that the relevant chronic disease was present, even if not coded.

Analysis {#s2d}
--------

The prevalence of CKD stages derived from the use of the MDRD and CKD-EPI equations was calculated using the size of the registered population aged 18 years and over as the denominator. Demographic and clinical features of patients reclassified from CKD stage 3a to stage 2 by using the CKD-EPI equation were compared with patients who remained in stage 3a. Next, we specifically described characteristics and cardiovascular risk profile of patients whose CKD stage 3a was changed to stage 2 who had no diagnosed comorbidity that would otherwise have necessitated their participation in a cardiovascular risk management programme. To assess cardiovascular risk profile we applied the EuroSCORE 10 year risk for CVD.[@R5] To ensure conservative estimation we assumed negative smoking status when lacking. Continuous data were compared using t tests and categorical data were analysed using χ^2^ tests. Analysis was conducted using SPSS V.20.0 (IBM PASW statistics 20).

Results {#s3}
=======

Practice population {#s3a}
-------------------

The 47 study practices serve a population of 207 469 people of whom 162 562 were over 18 years of age. Between 2008 and 2011, 37% of all adults registered with these practices (n=60 673) had their serum creatine measured. In the over 65 age group this figure rose to 71% (20 959 out of 29 591).

Study population {#s3b}
----------------

The use of the CKD-EPI equation changed the CKD stage for 20% of patients (n=12 278) with a measured serum creatine value. This reclassification resulted in a 16% net reduction in the total number of individuals with CKD stage 3 or worse: 1428 patients were reclassified from stage 3a to stage 2, whereas 195 patients were reclassified from stage 2 to stage 3a ([table 1](#BMJOPEN2013003631TB1){ref-type="table"}). As a consequence the prevalence of detected CKD stages 3--5 declined from 4.8% to 4.0% in the total adult population.

###### 

Reclassification of primary care patients when using CKD-EPI instead of MDRD

  eGFR categories with MDRD (mL/min/1.73 m^2^)   eGFR categories with CKD-EPI (mL/min/1.73m^2^)   Total                             
  ---------------------------------------------- ------------------------------------------------ -------- ------ ------ ----- ---- --------
  \>90                                           15 195                                           741      0      0      0     0    15 936
  60--89                                         9580                                             27 184   195    0      0     0    36 959
  45--59                                         0                                                1428     4338   146    0     0    5912
  30--44                                         0                                                0        106    1345   63    0    1514
  15--29                                         0                                                0        0      9      290   7    306
  \<15                                           0                                                0        0      0      3     43   46
  Total                                          24 775                                           29 353   4639   1500   356   50   60 673

CKD-EPI, chronic kidney disease epidemiological collaboration; eGFR, estimated-glomerular filtration rate; MDRD, Modification of Diet and Renal Disease Study.

Thirty-two per cent (n=19 235) of those who had a serum creatine measurement also had a urine assessment to evaluate albuminuria, and the numbers of patients with different levels of albuminuria are shown in [table 2](#BMJOPEN2013003631TB2){ref-type="table"}, stratified by eGFR category using both MDRD and CKD-EPI eGFRs. Overall in those tested, the prevalence of microalbuminuria was 12.1% (n=2322) and of macroalbuminuria was 1% (n=284). Of the patients reclassified from CKD stage 3a to stage 2 eGFR range, albuminuria was tested for in 43% (n=617) and the prevalence of microalbuminuria was 8.6% (n=53) and of macroalbuminuria was 1.5% (n=9).

###### 

Numbers of patients with proteinuria according to estimated eGFR category with either MDRD or CKD-EPI in 19235 primary care patients with available results of urine analysis

                      eGFR categories (mL/min/1.73 m^2^                             
  ------------------- ----------------------------------- ------- ------ ----- ---- ---
  MDRD eGFR                                                                         
   Macroalbuminuria   37                                  97      67     55    21   7
   Microalbuminuria   437                                 1140    489    219   35   2
   No albuminuria     3016                                10768   2297   496   51   1
  CKD-EPI eGFR                                                                      
   Macroalbuminuria   43                                  98      61     53    21   8
   Microalbuminuria   516                                 1089    442    226   47   2
   No albuminuria     4678                                9617    1783   490   58   3

CKD-EPI, chronic kidney disease epidemiological collaboration; eGFR, estimated-glomerular filtration rate; MDRD, Modification of Diet and Renal Disease Study.

Patients reclassified out of CKD compared to patients remaining in stage 3a {#s3c}
---------------------------------------------------------------------------

Compared to patients whose CKD stage remained 3a, those who were reclassified to stage 2 range eGFR using the CKD-EPI equation were younger, more were female, with less microalbuminuria, a comparable prevalence of macroalbuminuria, fewer comorbidities and were prescribed fewer antihypertensive and lipid-lowering drugs ([table 3](#BMJOPEN2013003631TB3){ref-type="table"}). Systolic blood pressure was significantly lower and diastolic blood pressure significantly higher in patients reclassified out of CKD. Total cholesterol and low-density lipoprotein (LDL)-cholesterol were significantly higher in this group.

###### 

Characteristics of patients reclassified out of CKD compared to those who remained in stage 3a

  Variable                                                    Remained in stage 3a (N=4338)   No of available data   Reclassified out of CKD (N=1428)   No of available data   P for comparison
  ----------------------------------------------------------- ------------------------------- ---------------------- ---------------------------------- ---------------------- ------------------
  Age                                                         74.0 (9.5)                      4338                   60.3 (9.5)                         1428                   \<0.0001
  Female                                                      61% N=2654                      4338                   76% N=1087                         1428                   \<0.0001
  Cardiovascular disease                                      36% N=1566                      4338                   18% N=250                          1428                   \<0.0001
  Hypertension                                                57% N=2463                      4338                   47% N=666                          1428                   \<0.0001
  Diabetes                                                    26% N=1134                      4338                   17% N=243                          1428                   \<0.0001
  None (also excluding albuminuria)                           21% N=924                       4338                   39% N=557                          1428                   \<0.0001
  Statins                                                     46% N=2000                      4338                   33% N=475                          1428                   \<0.0001
  ACE inhibitors and/or Angiotensin II receptor antagonists   54% N=2349                      4338                   37% N=533                          1428                   \<0.0001
  Diuretics                                                   43% N=1862                      4338                   26% N=367                          1428                   \<0.0001
  Creatine in µmol/L                                          102 (14.3)                      4338                   93 (11.4)                          1428                   \<0.0001
  Cholesterol/HDL ratio                                       4.2 (1.4)                       3338                   4.3 (1.6)                          1118                   0.020
  Total cholesterol in mmol/L                                 5.1 (1.2)                       3498                   5.4 (1.1)                          1157                   \<0.0001
  HDL in mmol/L                                               1.31 (0.40)                     3454                   1.36 (0.41)                        1150                   \<0.0001
  LDL in mmol/L                                               3.05 (1.02)                     3451                   3.31 (1.01)                        1150                   \<0.0001
  Triglycerides in mmol/L                                     1.65 (0.83)                     3458                   1.64 (1.05)                        1156                   0.616
  Albumin/creatine ratio\*                                    1.0 (0.9--2.5)                  2092                   0.9 (0.7--1.2)                     583                    \<0.0001
  Albumin urine in mg/L\*                                     6.0 (2.9--17.0)                 1174                   3.0 (2.0--8.0)                     348                    \<0.0001
  Microalbuminuria                                            410                             2161                   53                                 617                    \<0.0001
  Macroalbuminuria                                            55                              2161                   6                                  617                    0.113
  Diastolic blood pressure in mm Hg                           78.4 (9.4)                      3540                   81.5 (9.0)                         1043                   \<0.0001
  Systolic blood pressure in mm Hg                            143.3 (17.5)                    3540                   139.7 (15.8)                       1042                   \<0.0001

\*Values are mean (SD) or median (first, third quartile). Percentages of prevalence are calculated with the denominator of available data.

HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Patients reclassified out of CKD without other diagnosed comorbidities {#s3d}
----------------------------------------------------------------------

A total of 463 patients (32% of those reclassified out of CKD) would be removed from a cardiovascular risk management programme as they were not diagnosed with other comorbidities ([table 4](#BMJOPEN2013003631TB4){ref-type="table"}). Cholesterol measurement was performed in 64% of patients. The majority of patients had not had an albuminuria assessment. Blood pressure was measured in 218 patients and 111 (51%) of them had elevated values ≥140/90 mm Hg requiring further monitoring. Similarly, 20 of 172 patients (12%) with sufficient data to complete cardiovascular risk assessment had a EuroSCORE 10 year CVD risk of \>20%.

###### 

Characteristics of patients reclassified out of CKD without diagnosed comorbidity

                                                              Mean (SD)         No of patients with available data
  ----------------------------------------------------------- ----------------- ------------------------------------
  Age                                                         56.6 (10.0)       463
  Female                                                      79%               463
  Creatine in µmol/L                                          97 (11.9)         463
  Chol/HDL ratio                                              4.4 (1.6)         285
  Total cholesterol in mmol/L                                 5.8 (1.0)         295
  HDL in mmol/L                                               1.44 (0.43)       290
  LDL in mmol/L                                               3.78 (0.89)       289
  Triglycerides in mmol/L                                     1.42 (0.76)       289
  Albumin/creatine ratio                                      0.9 (0.5--0.9)    65
  Albumin urine in mg/L                                       2.9 (2.0--5.25)   38
  Diastolic blood pressure in mm Hg                           81.8 (9.1)        218
  Systolic blood pressure in mm Hg                            138.0 (16.7)      218
  Either systolic or diastolic blood pressure ≥140/90 mm Hg   111               218
  EuroSCORE 10 year cardiovascular disease risk ≥20%          20                172

Patients reclassified into a CKD diagnosis {#s3e}
------------------------------------------

A total of 195 patients were reclassified from stage 2 to stage 3a CKD, and of these, 166 (85%) had existing comorbidities that would already have identified them for cardiovascular risk assessment. Among the 29 patients who had no identifiable comorbidity, their mean age was 85.4 years (SD 5.1, youngest 76 years) and in the 11 patients with recorded BP, mean values were 137.5 mm Hg (SD 13.7)/71.4 mm Hg (5.4). Of the eight patients with sufficient data for CVD risk scoring, six patients were \>20%, although all were outside the age range for accurate scoring and may qualify for high-risk status on age alone.

Discussion {#s4}
==========

Principal findings {#s4a}
------------------

Application of the CKD-EPI equation to our study population resulted in a net 16% decrease (prevalence from 4.8% to 4.0%) in the total number of individuals with CKD stage 3 or worse based on eGFR criteria. Patients reclassified from stage 3a to stage 2 were younger, more were female with lower prevalence of comorbidities and a differential effect was seen on blood pressure with lower systolic but higher diastolic mean values. Although 32% of patients reclassified out of stage 3a had no documented comorbidity that would entail annual CVD risk factor assessment as part of a chronic disease management programme, an estimated 12% of these patients did indeed have elevated CVD risk. Not all reclassified patients had an adequate CVD risk factor assessment so our results may underestimate the scale of this problem, although it is still likely that CKD-EPI reclassification has reduced the number of low-risk patients in stage 3.

Differences in prevalence of prescribed lipid lowering therapy may explain why higher total cholesterol and LDL levels were seen in patients who were reclassified to a higher eGFR value, above the 60 mL/min/1.73 m^2^ cut-off. Higher prevalence of comorbidities, in patients in CKD stage 3 using CKD-EPI estimation, are indications for improved risk factor control for primary and secondary prevention are likely to explain the greater statin prescribing and lower lipid levels in patients retaining a stage 3 CKD diagnosis. However, the differences in blood pressure are not explained by differences in antihypertensive prescribing, due to the differential effect on systolic and diastolic blood pressure.

Strengths and limitations of this study {#s4b}
---------------------------------------

One of the strengths of our study is the use of routine general practice data from a large population which enhances the generalisability of our results. In the absence of a screening programme, existing CKD diagnoses are made from clinician-directed testing and so cannot provide true population prevalence. However, we were able to include a large proportion of the (potential) CKD population as creatine results were known in 71% of patients over 65 years of age. A strength of the analysis of patients reclassified from stage 3 CKD to stage 2 eGFR range is that we made the conservative assumption that patients prescribed medication used to treat comorbidities did indeed have that comorbidity, even if it was not coded in the medical record. This will have the effect of reducing the number of patients in the subgroup without comorbidity reclassified out of a CKD diagnosis, and the impact that we did find is likely to underestimate the effect of reclassification. Furthermore, our study accurately reflects the changes in CKD stage and status that will arise from use of the CKP-EPI formula in current clinical practice with clinician-directed testing.

A limitation of this study is that our classification of patients was based on a single creatine result, whereas guidelines recommend two measurements ≥3 months apart before making a diagnosis. However, this is unlikely to affect the proportional changes seen to a great extent given the size of our dataset and is in line with the approach used in most CKD studies.[@R11] [@R12] [@R18; @R19; @R20] Albuminuria and cardiovascular risk factor assessment were incomplete and this highlight an area for quality improvement in general practice. However, despite the low usage of albuminuria assessment, our estimates of the gains and losses in CKD diagnoses are likely to be reliable. We did not have ethnicity data and assumed our population to be Caucasian. This assumption was based on ethnicity data from the Statistics Netherlands that shows 92% of the population is Caucasian in the eastern Netherlands.[@R21] Both MDRD and CKD-EPI equations estimate true GFR and are therefore prone to some degree of error.

Comparison with existing literature {#s4c}
-----------------------------------

In other studies, a similar decrease in CKD prevalence was found: from 4.2% to 3.9% and 4.9% to 4.4% in two large adult UK population-based studies,[@R18] and from 5.41% to 4.80% in the Quality Improvement in CKD trial.[@R22] Also, CKD stage alteration in one-fifth of all patients with a creatine measurement by use of the CKD-EPI equation is a figure consistent with previous estimates.[@R11]

Cohort studies stratifying patients at baseline with reclassified CKD stages using CKD-EPI eGFRs report lower cardiovascular events in these patient groups during follow-up,[@R13; @R14; @R15] suggesting that overall, risk prediction is improved. Two studies that analysed the characteristics of patients reclassified out of a CKD diagnosis using CKD EPI are in agreement with our results, finding that these patients were predominantly women, of younger age and with less diabetes compared to those whose CKD stage remained unchanged.[@R19] [@R23] White *et al*[@R19] did not report diastolic blood pressure or LDL-cholesterol levels, but found that those reclassified out of CKD had lower systolic blood pressure, similar total cholesterol levels and lower triglycerides levels and a lower 10-year CVD risk. Although we also found lower systolic blood pressure levels, we found higher total (and LDL) cholesterol and no reduction in triglyceride levels. The differential effect on systolic and diastolic blood pressure may be explained by the fact that the reclassified patients in our study had a younger mean age. Diastolic blood pressure has been shown to be high in early middle age and then fall in older age as systolic blood pressure increases.[@R24] Patients with a CKD-EPI eGFR sufficiently higher than their MDRD eGFR to lose their CKD diagnosis are young enough to exhibit this effect.

Korhonen *et al*[@R20] found no significant differences in cardiovascular risk factors between those reclassified and those remaining in the same CKD stage when the CKD-EPI formula was used, but the study size (n=1747)was probably too small to detect the differences we identified. No previous study has examined medication use.

Meaning of the study {#s4d}
--------------------

Introduction of CKD-EPI to calculate eGFR can be expected to lower primary care workload and reduce treatment and costs in patients who overall have low cardiovascular risk. While the CKD-EPI equation shows greater calibration than the MDRD equation in that it more accurately stratifies patients in terms of their cardiovascular risk, we have found that by using routinely collected data in primary care, patients reclassified out of CKD had a more favourable cardiovascular profile in terms of age and comorbidity compared to patients who remained in stage 3a. However, there is a small group of patients with elevated cardiovascular risk who will no longer be detected and managed.

Unanswered questions and future research {#s4e}
----------------------------------------

Uncertainty remains about the impact on patient cardiovascular follow-up in those who lose their CKD diagnosis with use of the CKD-EPI formula. Although fewer cardiovascular events are seen in patients reclassified from retrospective observational data,[@R13; @R14; @R15] their care would have been guided by MDRD staging rather than the less severe CKD stage seen with CKD-EPI. Prospective follow-up studies are therefore required to appropriately determine the impact of CKD-EPI GFR estimation on cardiovascular events.

Current guidelines apply a fixed eGFR threshold to define CKD with the result that some patients will not be diagnosed with CKD in the presence of reduced renal function for their age group. This effect may be particularly relevant in younger patients, who may for example, have a 'normal' eGFR of 80 mL/min/1.73 m2 which is 'normal' according to Dutch guidelines[@R4] yet it is significantly lower than the average GFR in people of a similar age.[@R25] It may be more appropriate to report the statistical deviation of eGFR values from age-matched population mean and to highlight those that lie below a given percentile for further assessment and cardiovascular risk assessment. The CKD-EPI equation would make such an approach more feasible since it can be used to accurately report on eGFR \>60 mL/min/1.73 m^2^.[@R8] Further research is therefore needed to determine the feasibility of age-matched eGFR reporting to guide patient management.
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